Shilpa Medicare launches generic Axitinib to treat advanced kidney cancer
AXISHIL is used to treat patients suffering from Advanced Renal Cell Carcinoma (RCC).;
Advertisement
Karnataka: Shilpa Medicare Limited has launched the Indian branded generic of Axitinib, a tyrosine kinase inhibitor drug with a brand name AXISHIL.
AXISHIL is available as 1 mg & 5 mg tablets in a pack of 14's Tablets in one bottle.
AXISHIL is used to treat patients suffering from Advanced Renal Cell Carcinoma (RCC).
This novel targeted therapy attacks cancer cells without damaging normal cells, thus causing fewer side effects. There has been a significant improvement in survival rates in patients with advanced renal cancer due to the advent of this novel targeted therapy.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.